Insider buying last 90 days
No open-market insider purchases were filed for PACS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every PACS insider filing, plotted on the chart in Gekko.Open PACS in Gekko
Gekko Brief
AI summaryThis week's news around PACS Group centers on a leadership transition, with John Mitchell retiring as Chief Legal Officer effective September 18 and Patrick J. Murphy stepping in immediately; shares rose 2% in after-hours trading following the announcement. Separately, law firm Halper Sadeh LLC is investigating whether PACS officers and directors breached fiduciary duties to shareholders, and other coverage has flagged insider selling activity over the last three months even as overall insider transactions over the past year have skewed toward purchases. A comparison piece also weighed PACS against peer InnovAge on profitability and valuation measures.
PACS closed at $43.06, up 4.3%, sitting between its 50-day average of $44.27 and 200-day average of $38.80, with mixed short-term trend signals. The stock's one-month return stands at -2.7% while its six-month return is 40.8%. The GekkoIndex reads 60.5, placing it in the Accumulation zone, though the index has eased 4.1 points over the past five sessions. Price remains 14.2% below Gekko Fair Value of $50.20.
The next earnings report is scheduled for 9 November, 41 days out and beyond a typical 20-trading-day holding window. At last report on 4 August, PACS beat EPS estimates ($0.63 actual versus $0.55 estimate) with a 2.6% price reaction; it has beaten estimates in 5 of its last 8 quarters. No insider, Congress, or unusual options activity appears in the current windows, and analyst consensus from 5 firms rates the stock a buy with a $59 target.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
PACS price vs fair value
Close $43.06200-day averageGekko Fair Value $50.20
PACS quick facts
- Market cap
- $6.82B
- P/E ratio
- 24
- Forward P/E
- 15.5
- EPS, TTM
- $1.73
- Revenue, TTM
- $5.55B
- Profit margin
- 4.9%
- Dividend yield
- —
- Beta
- -0.13
- Volume
- 1.10M avg 759,233
- 1-year return
- +239.3%
- Typical daily move
- ±3.6%
- Typical 20-day move
- ±10.7%
- 50-day average
- $44.27
- 200-day average
- $38.80
- Next earnings
- Nov 9
- Shares outstanding
- 158.3M
PACS swing-trade checklist
PACS scores 3 supportive, 1 mixed and 0 headwinds across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $43.06 sits between the 50-day ($44.27) and 200-day ($38.80) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
60.5, Accumulation
Reading 60.5 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
14.2% below
Price is 14.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 41 days
Next report Nov 9, 2026, 41 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
PACS stock chart and price history
PACS closed at $43.06 on Sep 28, 2026, +239.3% over the past year, inside a 52-week range of $10.31 to $49.49.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −2.7%
- 3 months
- +7.8%
- 6 months
- +40.8%
- 1 year
- +239.3%
The full PACS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PACS in Gekko
Follow PACS through every session
Put PACS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PACS in GekkoFree for 7 days. No credit card required.
About PACS
PACS functions as a parent company overseeing a group of businesses centered on care for patients after hospital discharge or acute treatment. This work spans running care facilities, supplying trained clinical staff, and handling the supporting services those facilities need to function. It is also recognized for housing options aimed at older adults, including focused senior care, assisted living, and independent living settings offered in particular communities.
Its operations bring together two related strands, one centered on clinical and facility-driven care, the other on residential living for seniors, giving it a presence across multiple points in a person's care journey.
Jason Murray and Mark Hancock started the company in 2013, and it now runs its operations from Farmington, Utah. Its stock trades on the NYSE under the ticker PACS.
- Listed
- NYSE
- Sector
- Health services
- Industry
- Hospital/Nursing management
- Website
- pacs.com
PACS GekkoIndex: the smart money zone
PACS’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.5, in the Accumulation zone, down 4.1 points over five sessions.
60.5Accumulation
Down 4.1 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 36 | +2.7% | +6.9% | ||
| Accumulation (current zone) | 184 | +1.3% | +5.3% | ||
| Neutral | 346 | +0.9% | +6.3% | ||
| Distribution | 42 | +1.6% | +1.1% | ||
| Selling | 4 | Too few readings yet | |||
Average PACS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the PACS price, zone by zone.Track PACS in Gekko
Is PACS stock overvalued? Gekko Fair Value
PACS trades 14.2% below Gekko Fair Value of $50.20, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what PACS shares are worth, recalculated every trading day.
$50.20
Gekko Fair Value, Sep 26, 2026
14.2% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open PACS in Gekko
PACS insider and Congress trading
No open-market insider purchases were filed for PACS, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in PACS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for PACS, plotted on the chart in Gekko.Open PACS in Gekko
Buybacks
PACS has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2025
- $440K
- As a share of market cap
- 0.01%
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold PACS.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
PACS earnings: next date and track record
PACS reports on Nov 9, 2026 (41 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 9, 2026
41 days away
- EPS estimate
- $0.57
- Revenue estimate
- $1.46B
5 of 8reports beat the EPS estimate
±16.6%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- PACS Group reported Q2 2026 revenue growth of 9.1% and adjusted EBITDA growth of 25% year-over-year, demonstrating meaningful margin expansion. Same-store revenue grew 5.8% with occupancy up 150 basis points; overall occupancy increased 180 basis points and skilled mix improved 100 basis points. As of June 30, PACS operated 324 facilities across 17 states with 35,631 total beds and ~48,000 employees. The company attributes performance to its locally-led, centrally-supported operating model.
- Guidance
- Management reaffirmed 2026 revenue and adjusted EBITDA expectations, citing continued portfolio maturation, occupancy improvement, and skill mix strengthening as key drivers. Forward guidance details were referenced in the press release and investor presentation.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $0.63 est $0.55 | $1.43B est $1.41B | +2.6% |
| May 11, 2026 | $0.64 est $0.41 | $1.42B est $1.36B | +22.1% |
| Feb 26, 2026 | $0.43 est $0.48 | $1.36B est $1.38B | −7.1% |
| Nov 19, 2025 | $0.32 est $0.45 | $1.34B est $1.11B | +81.2% |
| Aug 18, 2025 | $0.45 est $0.48 | — | +3.0% |
| May 19, 2025 | $0.42 est $0.40 | — | −2.5% |
| Feb 26, 2025 | $0.39 est $0.35 | — | −3.2% |
| Nov 8, 2024 | $0.34 est $0.33 | — | +10.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
PACS stock forecast and analyst price targets
Analysts’ average 12-month price target for PACS is $59.00, +37.0% from the last close, from 5 firms rating the stock in the last 90 days.
$59.00consensus 12-month target, +37.0% from the last close
Now $43.06Avg $59.00
Low $57High $60
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 8 | J.P. Morgan | $58 | +34.7% |
| Sep 8 | J.P. Morgan | $58 | +34.7% |
| Sep 4 | J.P. Morgan | $58 | +34.7% |
| Sep 2 | Truist Financial | — | — |
| Aug 10 | Oppenheimer | $57 | +32.4% |
+5.3%average 20-day move after past Accumulation readings
±3.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
PACS market cap and key statistics
PACS’s market cap is $6.82B, with a P/E ratio of 24 and revenue of $5.55B over the last twelve months.
Valuation
- Market cap
- $6.82B
- P/E ratio
- 24
- Forward P/E
- 15.5
- EPS, TTM
- $1.73
- Gekko Fair Value
- $50.20
Trading
- Volume
- 1.10M
- Avg volume, 20 days
- 759,233
- 52-week high
- $49.49
- 52-week low
- $10.31
- Shares outstanding
- 158.3M
Financials
- Revenue, TTM
- $5.55B
- Profit margin
- 4.9%
- Return on equity
- 27.9%
- Quarterly earnings growth, YoY
- +51.6%
Risk and income
- Beta
- -0.13
- Typical daily move
- ±3.6%
- Typical 20-day move
- ±10.7%
PACS stock news this week
Coverage of PACS this week reads neutral: 2 positive, 3 neutral and 1 negative headlines.
- Law firm investigates PACS Group officers for possible breaches harming shareholders.Pluang, Sep 26
- Did PACS Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?The Transylvania Times, Sep 26
- Critical Contrast: InnovAge (NASDAQ:INNV) and PACS Group (NYSE:PACS)Defense World, Sep 24
- Don't Ignore The Insider Selling In PACS GroupMoomoo, Sep 22
- John Mitchell to Retire as Chief Legal Officer and Secretary of PACS GroupTradingView, Sep 22
- PACS Group names Patrick Murphy as chief legal officerInvesting.com, Sep 21
PACS peers
PACS’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| HCAHCA Healthcare | Neutral | 12.8% above |
| THCTenet Healthcare | Neutral | 9.4% below |
| UHSUniversal Health Services | Neutral | 20.1% below |
| CHEChemed | Neutral | 5.5% below |
| NHCNational HealthCare | Neutral | 29.0% above |
| BKDBrookdale Senior Living | Buying | 11.8% below |
A peer links to its own page where one exists.
PACS stock FAQ
What is PACS’s market cap?
PACS’s market cap is $6.82B at the Sep 28, 2026 close of $43.06, with 158.3M shares outstanding. The shares trade on a P/E ratio of 24.
What is the PACS stock forecast?
The consensus analyst 12-month price target for PACS is $59.00, +37.0% from the last close. Of the 5 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is PACS stock overvalued or undervalued?
On Gekko’s estimate PACS is undervalued: the Sep 28, 2026 close of $43.06 is 14.2% below Gekko Fair Value of $50.20. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does PACS report earnings next?
PACS is expected to report on Nov 9, 2026 (41 days away). Analysts expect earnings of $0.57 per share on revenue of $1.46B. PACS beat the earnings estimate in 5 of its last 8 reports, moving 16.6% on average across the report.
What is PACS’s 52-week high and low?
PACS’s 52-week high is $49.49 and its 52-week low is $10.31; it closed at $43.06 on Sep 28, 2026, +239.3% over the past year.
Is PACS stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 4 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See PACS the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.